Abd Al-Kader Al Salihy, D., Abdul Ilah Al Nakash, M., Abdul Razzaq Mshimesh, B. (2011). Ondansetron versus Metoclopramide, both Combined with Dexamethasone, in Prevention of Emesis induced by Chemotherapy. , 0(0), 13-26.
Dalia Abd Al-Kader Al Salihy; Munoor Abdul Ilah Al Nakash; Bahir Abdul Razzaq Mshimesh. "Ondansetron versus Metoclopramide, both Combined with Dexamethasone, in Prevention of Emesis induced by Chemotherapy". , 0, 0, 2011, 13-26.
Abd Al-Kader Al Salihy, D., Abdul Ilah Al Nakash, M., Abdul Razzaq Mshimesh, B. (2011). 'Ondansetron versus Metoclopramide, both Combined with Dexamethasone, in Prevention of Emesis induced by Chemotherapy', , 0(0), pp. 13-26.
Abd Al-Kader Al Salihy, D., Abdul Ilah Al Nakash, M., Abdul Razzaq Mshimesh, B. Ondansetron versus Metoclopramide, both Combined with Dexamethasone, in Prevention of Emesis induced by Chemotherapy. , 2011; 0(0): 13-26.

Ondansetron versus Metoclopramide, both Combined with Dexamethasone, in Prevention of Emesis induced by Chemotherapy

AL-yarmouk Journall
Article 1, Volume 0, Issue 0, 2015, Pages 13-26
Authors
Dalia Abd Al-Kader Al Salihy; Munoor Abdul Ilah Al Nakash; Bahir Abdul Razzaq Mshimesh
Abstract
Prophylactic use of 5-hydroxytryptamine3 receptor antagonists after the first 24 h of exposure to emetic chemotherapy (to decrease the incidence of delayed phase emesis) cause an increase in the cost of treatment.
Statistics
Article View: 157
PDF Download: 112


Journal Management System. Powered by iJournalPro.com